{"id":47354,"date":"2022-08-16T19:01:40","date_gmt":"2022-08-16T17:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/"},"modified":"2022-08-16T19:01:40","modified_gmt":"2022-08-16T17:01:40","slug":"growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/","title":{"rendered":"Growth Opportunities for Digital Biomarkers in Drug Development &#8211; Focus on Neurology, Oncology, and Cardiology &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5640247\/growth-opportunities-for-digital-biomarkers-in?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=44nj4n&amp;utm_campaign=1738946+-+Growth+Opportunities+for+Digital+Biomarkers+in+Drug+Development+-+Focus+on+Neurology%2C+Oncology%2C+and+Cardiology&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Growth Opportunities for Digital Biomarkers in Drug Development&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact.\n<\/p>\n<p>\nPharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate.\n<\/p>\n<p>\nDigital biomarkers derived from wearable sensors and advanced algorithms offer an opportunity to analyze the response of investigational medical products in clinical trials continuously and remotely. Digital biomarkers eliminate the need for frequent clinic visits to monitor the patient&#8217;s health status.\n<\/p>\n<p>\nThe halting of clinical trials because of the COVID-19 pandemic has fueled digital biomarker adoption for remote patient monitoring in clinical practices and clinical trials. Remote patient monitoring is imperative for pharmaceutical companies to conduct efficient clinical trials, save costs, and decide on proceeding with or discontinuing an investigational drug.\n<\/p>\n<p>\nEfforts are underway by market participants to transform digital biomarkers into digital measurements or endpoints in clinical trials. Digital biomarkers are instrumental in assessing the efficacy and safety of the therapy in DCTs and timely patient recruitment.\n<\/p>\n<p>\nDigital biomarkers offer an opportunity for pharmaceutical companies to advance research in complex diseases, such as AD and PD, and to find novel biomarkers that demonstrate the effectiveness of an investigational drug on a patient&#8217;s disease condition in clinical trials.\n<\/p>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Strategic Imperatives<\/strong>\n<\/p>\n<ul>\n<li>\nWhy Is It Increasingly Difficult to Grow? The Strategic Imperative: Factors Creating Pressure on Growth\n<\/li>\n<li>\nThe Strategic Imperative\n<\/li>\n<li>\nThe Impact of the Top 3 Strategic Imperatives on Digital Biomarkers for the Drug Development Industry\n<\/li>\n<li>\nGrowth Opportunities Fuel the Growth Pipeline Engine\n<\/li>\n<li>\nResearch Methodology\n<\/li>\n<\/ul>\n<p>\n<strong>2. Growth Opportunity Analysis<\/strong>\n<\/p>\n<ul>\n<li>\nAmidst the Ambiguity among Researchers, Regulatory Bodies Have Provided a Digital Biomarker Definition for Clear Expectations\n<\/li>\n<li>\nDigital Biomarkers Can Explain a Health Variability in Humans\n<\/li>\n<li>\nDigital Biomarkers Are Inexpensive, Non-invasive, and Comparatively New in Clinical Practice\n<\/li>\n<li>\nThe Role of Digital Biomarkers in Expediting the Drug Development Process Will Grow Significantly\n<\/li>\n<li>\nDigital Biomarkers Can Revolutionize Pharmaceutical Clinical Trials by Solving Major Challenges\n<\/li>\n<li>\nThe Development of Digital Biomarkers Improves Healthcare Delivery and Patients&#8217; Outcomes\n<\/li>\n<li>\nSeveral Literatures Present Digital Biomarker Utilization for Measuring Health Parameters or Monitoring Disease Conditions\n<\/li>\n<li>\nDigital Biomarkers Enable the Shift from Product-based to Service-based Model in the Pharmaceutical Industry\n<\/li>\n<li>\nGrowth Drivers\n<\/li>\n<li>\nGrowth Restraints\n<\/li>\n<li>\nScope of Analysis\n<\/li>\n<li>\nApplication Segmentation (Non-exhaustive)\n<\/li>\n<\/ul>\n<p>\n<strong>3. Growth Opportunity Analysis &#8211; Neurology<\/strong>\n<\/p>\n<ul>\n<li>\nComplexity of Neurological Disorders and Slow Drug Development Pose Significant Burdens on the Healthcare System\n<\/li>\n<li>\nDigital Biomarkers Can Accelerate Clinical Trials through Remote Patient Recruitment and Understanding Disease Mechanisms\n<\/li>\n<li>\nActivity and Vocal Biomarkers are the Emerging Digital Biomarkers in Neurology Clinical Trials\n<\/li>\n<li>\nGait, Speech, and Sleep Are the Main Biomarkers Digital Health Devices Collect in Clinical Trials\n<\/li>\n<li>\nPharmaceutical Companies and Universities Collaborate to Pursue Neurology Clinical Trials with Digital Biomarkers\n<\/li>\n<li>\nSmartphone App for Data Collection to Provide Digital Biomarkers and Continuous Monitoring of Trial Participants\n<\/li>\n<\/ul>\n<p>\n<strong>4. Growth Opportunity Analysis &#8211; Oncology<\/strong>\n<\/p>\n<ul>\n<li>\nCancer Results in Significant Unmet Needs Because of Limited Treatment Options and Disease Understanding\n<\/li>\n<li>\nDigital Biomarkers Enable Quality-of-life Assessments in Cancer Patients, Which Have Importance in Oncology Clinical Trials\n<\/li>\n<li>\nDigital Biomarkers for Oncology Are in the Nascent Stage of Adoption for Disease Management and Clinical Trials\n<\/li>\n<li>\nDigital Imaging Data Is the Main Digital Biomarker That Oncology Clinical Trials Collect\n<\/li>\n<li>\nMajor Companies Involved in Clinical Trials Utilizing Digital Biomarkers\n<\/li>\n<li>\nAI Technology for Identifying Digital Biomarkers for Precise Skin Cancer Diagnosis and Improved Treatment Selection\n<\/li>\n<li>\nGrowth Opportunity Analysis &#8211; Cardiology\n<\/li>\n<li>\nCardiology Complications Lead to Millions of Deaths Every Year, Costing Significant Economic and Healthcare Losses\n<\/li>\n<li>\nDigital Biomarkers Enable Remote Data Collection, Enhancing Safety Signal Accuracy and Eliminating Patient Inconvenience\n<\/li>\n<li>\nDigital Biomarkers in Cardiology Can Enhance Disease Diagnosis Accuracy\n<\/li>\n<li>\nHeart Rate, Blood Pressure, and Physical Activity Are Crucial Digital Biomarkers in Cardiology Clinical Trials\n<\/li>\n<li>\nKey Companies Involved in Clinical Trials Utilizing Digital Biomarkers\n<\/li>\n<li>\nTreatment Strategy Evaluation to Reduce Hospitalization-based Digital Biomarker Collection Via Remote Sensor Technology\n<\/li>\n<\/ul>\n<p>\n<strong>5. Regulatory Landscape<\/strong>\n<\/p>\n<ul>\n<li>\nFDA Guidance Provides Evidentiary Framework to Support Novel Biomarker Qualification\n<\/li>\n<li>\nPresenting High-quality Data, Benefits in Drug Development, and Evidence Are the Main Requirements for Qualification\n<\/li>\n<li>\nFDA&#8217;s Regulatory Initiatives Focus on Digital Health Technology Development and Guide Developers\n<\/li>\n<li>\nEMA Highlights Important Points to Consider for Successful Digital Biomarker Qualification that Support Approval of Medicinal Product\n<\/li>\n<\/ul>\n<p>\n<strong>6. Industry Assessment and Analysis<\/strong>\n<\/p>\n<ul>\n<li>\nMost Pharmaceutical Companies Depend on Technology Development Partners to Implement Digital Biomarkers in Clinical Trials\n<\/li>\n<li>\nPharmaceutical Companies Should Evaluate Their Reliance on Technology Developers and the Wearable Devices for Clinical Trials\n<\/li>\n<li>\nThe NCI and NIA Are the Leading Institutes Offering Grants for Digital Biomarker Research Focusing on Oncology and Neurology\n<\/li>\n<li>\nPrivate Funding Focuses on Novel Digital Biomarker Development and the Integration of Patient-facing Solutions with Digital Platforms\n<\/li>\n<li>\nPublic Funding Focuses on Evaluating Novel Digital Biomarkers for Early Disease Diagnoses, Such as Cancer and Neurological Diseases\n<\/li>\n<li>\nMarket Participants Adopt Partnerships and Collaborations to Accelerate Digital Biomarker Development\n<\/li>\n<li>\nEstablished Companies and Start-ups Are Developing Novel Digital Biomarkers to Enhance Clinical Trials or Advance Research\n<\/li>\n<li>\nNorth America Is the Largest Adopter of Digital Biomarkers due to Multiple Companies and Growing Research Funding\n<\/li>\n<li>\nCase Study: Chugai Pharmaceutical Co., Ltd. &#8211; Digital Biomarker Initiatives\n<\/li>\n<li>\nCase Study: Sanofi &#8211; Digital Biomarkers for CNS Clinical Trials\n<\/li>\n<li>\nDigital Biomarkers Will Play a Significant Role in DCT Implementation\n<\/li>\n<\/ul>\n<p>\n<strong>7. Patent Landscape<\/strong>\n<\/p>\n<ul>\n<li>\nDigital Biomarker Innovations Focus on Mobile Application, Software, and Analysis Algorithm Development\n<\/li>\n<li>\nNeurology and Oncology Are Focus Areas for the Top Patent Assignees Relating to Digital Biomarkers\n<\/li>\n<li>\nKey Patents\n<\/li>\n<\/ul>\n<p>\n<strong>8. Growth Opportunity Universe<\/strong>\n<\/p>\n<ul>\n<li>\nGrowth Opportunity 1: Digital Biomarkers for Patient Recruitment in Clinical Trials\n<\/li>\n<li>\nGrowth Opportunity 2: Digital Vocal Biomarkers for Remote, Contactless, Continuous, and Accurate Patient Monitoring in Clinical Trials\n<\/li>\n<li>\nGrowth Opportunity 3: Novel Digital Biomarker Development to Accurately Analyze the Patient&#8217;s Drug Response\n<\/li>\n<li>\nGrowth Opportunity 4: Analytical and Clinical Validation to Evaluate Digital Biomarkers for Use in Clinical Research\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5640247\/growth-opportunities-for-digital-biomarkers-in?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=44nj4n&amp;utm_campaign=1738946+-+Growth+Opportunities+for+Digital+Biomarkers+in+Drug+Development+-+Focus+on+Neurology%2C+Oncology%2C+and+Cardiology&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/izovqq<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;pr&#x65;&#x73;&#115;&#64;&#x72;&#x65;&#115;&#101;a&#x72;&#x63;&#104;a&#x6e;&#x64;&#109;&#97;r&#x6b;&#x65;&#116;s&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#114;&#x65;&#x73;s&#x40;&#114;e&#x73;&#101;a&#x72;&#99;&#x68;&#x61;n&#x64;&#109;a&#x72;&#107;e&#x74;&#115;&#x2e;&#x63;&#111;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Growth Opportunities for Digital Biomarkers in Drug Development&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact. Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47354","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Growth Opportunities for Digital Biomarkers in Drug Development&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact. Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-16T17:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Growth Opportunities for Digital Biomarkers in Drug Development &#8211; Focus on Neurology, Oncology, and Cardiology &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-16T17:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/\"},\"wordCount\":1051,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005776\\\/en\\\/1545848\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/\",\"name\":\"Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005776\\\/en\\\/1545848\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-16T17:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005776\\\/en\\\/1545848\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220816005776\\\/en\\\/1545848\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Growth Opportunities for Digital Biomarkers in Drug Development &#8211; Focus on Neurology, Oncology, and Cardiology &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Growth Opportunities for Digital Biomarkers in Drug Development&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact. Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-16T17:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Growth Opportunities for Digital Biomarkers in Drug Development &#8211; Focus on Neurology, Oncology, and Cardiology &#8211; ResearchAndMarkets.com","datePublished":"2022-08-16T17:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/"},"wordCount":1051,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/","name":"Growth Opportunities for Digital Biomarkers in Drug Development - Focus on Neurology, Oncology, and Cardiology - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg","datePublished":"2022-08-16T17:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220816005776\/en\/1545848\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/growth-opportunities-for-digital-biomarkers-in-drug-development-focus-on-neurology-oncology-and-cardiology-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Growth Opportunities for Digital Biomarkers in Drug Development &#8211; Focus on Neurology, Oncology, and Cardiology &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47354"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47354\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}